Status:
RECRUITING
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology
Lead Sponsor:
Centre Hospitalier Universitaire de Liege
Collaborating Sponsors:
Centre Hospitalier Régional de la Citadelle
SYSNAV
Conditions:
Neuromuscular Diseases
Obesity (Disorder)
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The ActiLiège-Adult study is a prospective, longitudinal, observational study designed to collect natural history data on adult patients with neurological or metabolic diseases affecting movement. Con...
Detailed Description
Following the qualification of the 95th centile of stride velocity (SV95C) as a primary digital endpoint in Duchenne muscular dystrophy (DMD), there is growing interest in extending such digital asses...
Eligibility Criteria
Inclusion
- Ambulant patients (i.e. able to walk 10 meters without assistance)
- Confirmed diagnosis by the investigator based on current gold standard in his/her disease (genetic testing, clinical criteria, etc.)
- Myotonic dystrophy type 1 (DM1) and Charcot-Marie-Tooth (CMT) patients should present sensitive of motor signs on physical examination.
- Myasthenic patients should be seropositive, and Myasthenia Gravis Foundation of America (MGFA) class II to IV.
- Patient with morbid obesity (Body Mass Index\> or = 35 at inclusion visit).
- Signed informed consent form by patient him/herself and patient willing and able to comply with all study procedures.
Exclusion
- Non-ambulant patients
- Patients with extreme cognitive disorders that limit their understanding of the exercises to be performed
- Patients who have undergone a surgical procedure or who have experienced recent trauma (within fewer than 6 months) affecting the upper or lower limbs
- A concomitant chronic or acute neurological, endocrine, infectious, allergic, or inflammatory pathology within the 3-week period immediately prior to inclusion
- Patients who are participating in an interventional clinical trial
- Pregnant or breastfeeding women
Key Trial Info
Start Date :
March 29 2024
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2030
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT07136844
Start Date
March 29 2024
End Date
December 1 2030
Last Update
August 22 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centre de référence des maladies neuromusculaire, Centre Hospitalier Régional de la Citadelle
Liège, Belgium, 4000